The creation of commercial cord blood banks rests on the promise of stem cell based regenerative medicine and marks the capitalization of human tissues within a future-oriented ?regime of hope?. This paper will present data from a survey of the international cord blood banking industry and will explore: (a) the way firms seek to commercialize cord blood as a new set of commodities; (b) the expectations and moral economy that are being constructed around this technology; and (c) how firms are acting as mediators of hope in what might be called a ?promissory bioeconomy?.
Martin, P. A., Brown, N., & Turner, A. (2008). Capitalizing hope: the commercial development of umbilical cord blood stem cell banking. New Genetics and Society, 27(2), 127-143. https://doi.org/10.1080/14636770802077074